Semler Scientific Stock Plummets to New 52-Week Low of $21.56

Semler Scientific, Inc., a microcap company in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 21.56 on November 14, 2025. This decline marks a significant downturn for the stock, which has experienced a 39.86% decrease over the past year, contrasting sharply with the S&P 500's positive performance of 13.19% during the same period.
The company's market capitalization stands at approximately USD 425 million, with a price-to-earnings (P/E) ratio of 24.00. Semler Scientific has not offered a dividend, and its debt-to-equity ratio is reported at -0.04, indicating a unique financial structure. The return on equity is relatively low at 3.43%, and the price-to-book ratio is 1.11.

Semler has faced challenges in its financial performance, reporting negative results for the last four consecutive quarters. The operating cash flow has reached a low of USD 12.45 million, while net sales for the latest quarter were recorded at USD 8.22 million. This consistent underperformance has contributed to the stock's current position in the market.